{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:21:03Z","timestamp":1794950463504,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ygyno.2022.05.018","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:23:12Z","timestamp":1654190592000},"page":"308-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma"],"prefix":"10.1016","volume":"166","author":[{"given":"Alexandra","family":"Diggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Y.","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Gockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Khoury-Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.05.018_bb0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/aogs.12930","article-title":"Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study","volume":"95","author":"Skorstad","year":"2016","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2012.01.021","article-title":"Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases","volume":"72","author":"Koivisto-Korander","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2022.05.018_bb0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/01.cco.0000127721.55676.f6","article-title":"Uterine leiomyosarcoma: present management","volume":"16","author":"Giuntoli","year":"2004","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0020","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: a review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PGP.0000000000000284","article-title":"Distant metastases in uterine Leiomyosarcomas: the wide variety of body sites and time intervals to metastatic relapse","volume":"36","author":"Bartosch","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0040","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1007\/s00330-016-4623-9","article-title":"Differentiation of uterine Leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis","volume":"27","author":"Lakhman","year":"2017","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0045","series-title":"SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute","author":"Howlader","year":"2020"},{"key":"10.1016\/j.ygyno.2022.05.018_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0060","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e46","article-title":"Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma","volume":"28","author":"Nasioudis","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0065","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG oncology\/gynecologic oncology group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer group study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.05.018_bb0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French sarcoma group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve Cancer Care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0090","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study","volume":"3","author":"Omura","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0100","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2022.05.018_bb0105","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2008.11.027","article-title":"Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study","volume":"112","author":"Hensley","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2016.07.110","article-title":"Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"143","author":"Bogani","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology\/gynecologic oncology group study","volume":"36","author":"Hensley","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.05.018_bb0140","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822003298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822003298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:21Z","timestamp":1758772821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822003298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0090825822003298"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.05.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}